Eye :: $2 million of potentially harmful cosmetic eye product seized in US

Harmful cosmetic eye products may increase the risk of optic nerve damage, macular edema, uveitis leading to decreased vision and blindness. At the request of the U.S. Food and Drug Administration, U.S. Marshals seized 12,682 applicator tubes of Age Intervention Eyelash, a product that may, in some users, lead to decreased vision. Authorities said the sales value of the seized tubes is approximately $2 million.

Depression :: Correcting poor vision in nursing home residents may decrease symptoms of depression

Nursing home residents who received eyeglasses for uncorrected refractive error were found to have improved quality of life and decreased symptoms of depression when compared to those with refractive error who had not received eyeglasses, according to a report in the November issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

Malaria :: Malaria vaccine candidate has promising safety, tolerability profile in infants

The first study to test GlaxoSmithKline’s (GSK) investigational RTS,S/AS02 malaria vaccine in African infants serves as the first proof of concept in this population that the vaccine has a promising safety and tolerability profile and reduces malaria parasite infection and clinical illness due to malaria, according to a paper published today online in The Lancet.

Alzheimer’s Disease :: New blood test to diagnose Alzheimer’s Disease

A team of international researchers reported they have identified a group of cell-signaling proteins found in blood that serve as a unique “voiceprint” that can not only be used to diagnose Alzheimer’s disease, but also classify and predict presymptomatic individuals who will eventually develop the memory-robbing disorder.

Multiple Sclerosis :: MS that runs in families appears more severe than non-familial MS

Magnetic resonance images (MRI) of a large group of patients with multiple sclerosis has provided the first evidence that those with a history of MS in their families show more severe brain damage than patients who have no close relatives with the disease.

HIV :: Global HIV Vaccine Enterprise names Alan Bernstein as Inaugural Executive Director

At the Keystone Symposium in Cape Town, the Global HIV Vaccine Enterprise announced the appointment of its first executive director and the opening of a new secretariat in New York City. Dr. Alan Bernstein, founding president of the Canadian Institutes of Health Research, will lead the international alliance of researchers, funders and advocates dedicated to speeding the search for an HIV vaccine.

Eye :: Discovery of retinal cell type ends 4-decade search

A research team combining high-energy physicists from the University of California, Santa Cruz, and neuroscientists from the Salk Institute in La Jolla, Calif., has discovered a type of retinal cell that may help monkeys, apes, and humans see motion. The team’s work appears in the October 10 issue of Journal of Neuroscience.

Cancer :: GSK & Synta Pharmaceuticals announce development and commercialisation collaboration for STA-4783 in oncology

GlaxoSmithKline (GSK) and Synta Pharmaceuticals Corp. announced the execution of a global collaboration agreement for the joint development and commercialisation of STA-4783, a first-in-class, small-molecule, oxidative stress inducer that is entering Phase 3 clinical development for the treatment of metastatic melanoma.

Macular Degeneration :: Elevated inflammatory marker may be linked to increased risk of age-related eye disease

High blood levels of C-reactive protein, a substance linked to inflammation, appear to be associated with an increased risk for age-related macular degeneration, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

Do NOT follow this link or you will be banned from the site!